CHIAs is a sub-recipient of the “Elimination of Mother-to-Child Transmission of HIV, Hepatitis B, and Syphilis at Antenatal Care Program” funded by L’Initiative France and the Centre of Infectiology Lao Christophe Merieux (CILM), the principalrecipient. This project targets three districts in Vientiane Province, aiming to integrate interventions to prevent mother-to-child transmission of HIV, syphilis, and hepatitis B. Local healthcare workers will be involved in designing tailored servicedelivery processes while engaging community stakeholders to raise awareness and increase demand for testing. The project will cover 17 villages in Viengkham, 59 in Phonhong, and 63 in Vangvieng, benefiting pregnant women and their infants—approximately 3,200 women during the pilot phase (first 18 months) and 8,800 during the expansion phase across the province. Partners will include 640 men in the pilot phase and at least 1,760 during expansion.
Project outcomes include:
1. Each health facility will develop and implement site-specific procedures for organizing HIV, syphilis, and hepatitis B testing in line with the Triple Elimination goal, providing care, treatment, prophylaxis, and referrals, while reporting prevalence andtreatment data to the Ministry.The percentage of pregnant women lacking access to reliable, rapid, and high-quality simultaneous testing will decrease by at least 50% in the first year.
2. The number of partners of pregnant women without access to reliable testing will decrease by at least 25%.
3. At least 95% of individuals aged 15-45 will understand when, where, and how to get tested for HIV, syphilis, and HBV.
4. At least 95% of pregnant women living with HIV, HBV, and syphilis will receive appropriate treatment to prevent mother-to-child transmission.
5. At least 95% of infants born to HIV-positive mothers will access early and appropriate treatment and care.
6. At least 95% of infants will receive the HB vaccine within 24 hours of birth, regardless of their mother’s HBV status.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close